SuanFarma-Header SuanFarma-Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Lead Product(s): Tertomotide

            Therapeutic Area: Neurology Product Name: GV1001

            Highest Development Status: Phase II Product Type: Peptide

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 30, 2021

            Details:

            The paper is titled 'Efficacy and safety of GV1001 in patients with moderate-to-severe Alzheimer's already receiving donepezil and contains an analysis of the overall data from the Phase II clinical trial for Alzheimer's disease conducted in Korea.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Lead Product(s): Tertomotide

            Therapeutic Area: Neurology Product Name: GV1001

            Highest Development Status: Phase II Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 23, 2020

            Details:

            GemVax's GV1001 Phase II trial evaluated the safety and efficacy of subcutaneous injection of GV1001 0.56 mg or 1.12 mg for six months in patients with moderate-to-severe Alzheimer's disease already receiving donepezil for more than three months, at 12 medical institutions.